Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ViPOR in Relapsed or Refractory CD10-Negative DLBCL and HGBCL-DH-BCL2
NCT06649812Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2025
- Primary completion
- Sep 2028
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, ibrutinib, prednisone, obinutuzumab, lenalidomide in diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), sponsored by National Cancer Institute. Started Oct 2025; status: recruiting.
02
Drugs
venetoclaxibrutinibprednisoneobinutuzumablenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT06649812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06649812.